跳至主要内容
临床试验/JPRN-jRCTs012180017
JPRN-jRCTs012180017已完成3 期

sefulness of using C-11 methionine PET in patient which suspected glioma - Usefulness of using C-11 methionine PET in patient which suspected glioma

Yamaguchi Shigeru0 个研究点目标入组 72 人开始时间: 2019年3月19日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
72

研究概览

简要总结

C-11 methionine-PET will be useful as an additional test for MRI by the following reasons. 1) C-11 methionine-PET detects tumor cells in MRI negative sites with high PPV. 2) In cases which have C-11 methionine-PET test, the rate of without additive effect was low. 3)There was few false negative case.

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • (1)The patients whose doctor plans a biopsy or tumor resection and whose tumor is suspected as primary glioma by board-certified diagnostic radiologists and board-certified neurosurgeons based on clinical manifestations, clinical courses, and MRI findings.
  • (2)The patients who or whose legal representative gave a written informed consent to this study.

排除标准

  • (1)The patients with a history of serious allergic reaction to C-11 methionine or F-18 FDG.
  • (2)Pregnant women, breast-feeding women, or women who may be pregnant
  • (3)The patients who is participating in other trials
  • (4)The patients who underwent C-11 methionine PET within 90 days
  • (5)The patients whose overall status is not satisfactory for surgical treatment
  • (6) The patients who cannot undergo contrast-enhanced MRI
  • (7) The patients whom investigators judged to be inadequate as candidates

研究者

发起方
Yamaguchi Shigeru

相似试验